TY - JOUR
T1 - Protective role of chaperone-mediated autophagy against atherosclerosis
AU - Madrigal-Matute, Julio
AU - de Bruijn, Jenny
AU - van Kuijk, Kim
AU - Riascos-Bernal, Dario F.
AU - Diaz, Antonio
AU - Tasset, Inmaculada
AU - Martín-Segura, Adrián
AU - Gijbels, Marion J.J.
AU - Sander, Bianca
AU - Kaushik, Susmita
AU - Biessen, Erik A.L.
AU - Tiano, Simoni
AU - Bourdenx, Mathieu
AU - Krause, Gregory J.
AU - McCracken, Ian
AU - Baker, Andrew H.
AU - Jin, Han
AU - Sibinga, Nicholas E.S.
AU - Bravo-Cordero, Jose Javier
AU - Macian, Fernando
AU - Singh, Rajat
AU - Rensen, Patrick C.N.
AU - Berbeé, Jimmy F.P.
AU - Pasterkamp, Gerard
AU - Sluimer, Judith C.
AU - Cuervo, Ana Maria
N1 - Publisher Copyright:
Copyright © 2022 the Author(s).
PY - 2022/4/5
Y1 - 2022/4/5
N2 - Chaperone-mediated autophagy (CMA) contributes to regulation of energy homeostasis by timely degradation of enzymes involved in glucose and lipid metabolism. Here, we report reduced CMA activity in vascular smooth muscle cells and macrophages in murine and human arteries in response to atherosclerotic challenges. We show that in vivo genetic blockage of CMA worsens atherosclerotic pathology through both systemic and cell-autonomous changes in vascular smooth muscle cells and macrophages, the two main cell types involved in atherogenesis. CMA deficiency promotes dedifferentiation of vascular smooth muscle cells and a proinflammatory state in macrophages. Conversely, a genetic mouse model with up-regulated CMA shows lower vulnerability to proatherosclerotic challenges. We propose that CMA could be an attractive therapeutic target against cardiovascular diseases.
AB - Chaperone-mediated autophagy (CMA) contributes to regulation of energy homeostasis by timely degradation of enzymes involved in glucose and lipid metabolism. Here, we report reduced CMA activity in vascular smooth muscle cells and macrophages in murine and human arteries in response to atherosclerotic challenges. We show that in vivo genetic blockage of CMA worsens atherosclerotic pathology through both systemic and cell-autonomous changes in vascular smooth muscle cells and macrophages, the two main cell types involved in atherogenesis. CMA deficiency promotes dedifferentiation of vascular smooth muscle cells and a proinflammatory state in macrophages. Conversely, a genetic mouse model with up-regulated CMA shows lower vulnerability to proatherosclerotic challenges. We propose that CMA could be an attractive therapeutic target against cardiovascular diseases.
KW - atherosclerotic plaques
KW - lipid challenge
KW - lysosomes
KW - proteolysis
KW - vascular disease
UR - http://www.scopus.com/inward/record.url?scp=85127423353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127423353&partnerID=8YFLogxK
U2 - 10.1073/pnas.2121133119
DO - 10.1073/pnas.2121133119
M3 - Article
C2 - 35363568
AN - SCOPUS:85127423353
SN - 0027-8424
VL - 119
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 14
M1 - e2121133119
ER -